We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · July 14, 2020

Ocrelizumab: Short vs Standard Infusion Time in MS

Neurology(R) neuroimmunology & neuroinflammation

 

Additional Info

Disclosure statements are available on the authors' profiles:

Neurology(R) neuroimmunology & neuroinflammation
Ocrelizumab Shorter Infusion: Primary Results From the ENSEMBLE PLUS Substudy in Patients With MS
Neurol Neuroimmunol Neuroinflamm 2020 Sep 01;[EPub Ahead of Print], HP Hartung

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading